Clinical Trials
11 trialsNCT05185947 2026-05-29
Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT05462717 2026-05-15
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Revolution Medicines, Inc.
Phase 1 Active not recruiting
NCT07487168 2026-05-15
Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Not yet recruiting
NCT05913674 2026-05-14
Technical Feasibility of Modified Early Post-Operative Intraperitoneal Chemotherapy (mEPIC)
Ciusss de L'Est de l'Île de Montréal
Phase 2 Recruiting
NCT04902872 2026-05-12
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
Cybrexa Therapeutics
Phase 1/2 Completed
NCT06128551 2026-04-23
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Revolution Medicines, Inc.
Phase 1/2 Recruiting
NCT04847063 2026-04-14
Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT05461430 2026-04-13
TraveraRTGx
Travera Inc
Completed
NCT04779554 2026-04-01
Flat Dose vs. Weight-based IP Chemotherapy for CRS/HIPEC
University of Kentucky
Phase 2 Recruiting
NCT04329494 2025-12-10
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
City of Hope Medical Center
Phase 1 Recruiting
NCT05277766 2025-07-01
PIPAC-NAL-IRI
University Hospital, Ghent
Phase 1 Recruiting